Four out of five biopharma companies think that the market opportunity for connected health products exceeds their traditional drug business, but adoption remains low, with only 20% of use
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
